Chávez-Valencia Venice, Orizaga-de-la-Cruz Citlalli, Lagunas-Rangel Francisco Alejandro
Department of Nephrology, Hospital General Regional Hospital No. 1, Instituto Mexicano del Seguro Social, Bosque de los Olivos No. 101. Av. La Goleta Mpo. Charo, Morelia 61301, Mexico.
Department of Surgical Sciences, Uppsala University, 75124 Uppsala, Sweden.
Diseases. 2022 Aug 19;10(3):53. doi: 10.3390/diseases10030053.
Coronavirus disease 2019 (COVID-19) is a disease caused by infection with the SARS-CoV-2 virus and has represented one of the greatest challenges humanity has faced in recent years. The virus can infect a large number of organs, including the lungs and upper respiratory tract, brain, liver, kidneys, and intestines, among many others. Although the greatest damage occurs in the lungs, the kidneys are not exempt, and acute kidney injury (AKI) can occur in patients with COVID-19. Indeed, AKI is one of the most frequent and serious organic complications of COVID-19. The incidence of COVID-19 AKI varies widely, and the exact mechanisms of how the virus damages the kidney are still unknown. For this reason, the purpose of this review was to assess current findings on the pathogenesis, clinical features, therapy, and mortality of COVID-19 AKI.
2019冠状病毒病（COVID-19）是一种由感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的疾病，是近年来人类面临的最大挑战之一。该病毒可感染大量器官，包括肺和上呼吸道、脑、肝、肾和肠道等。尽管肺部受损最为严重，但肾脏也难以幸免，COVID-19患者可发生急性肾损伤（AKI）。事实上，AKI是COVID-19最常见且严重的器官并发症之一。COVID-19相关急性肾损伤的发病率差异很大，病毒损伤肾脏的确切机制仍不清楚。因此，本综述的目的是评估目前关于COVID-19相关急性肾损伤的发病机制、临床特征、治疗及死亡率的研究结果。
